BRAF and cancer: Vemurafenib (PLX4032), a small-molecule inhibitor of BRAFV600E kinase, has high specificity for the BRAFV600E oncoprotein and exhibits a potently inhibitory effect on the MAPK/ERK cascade in BRAF-mutant cancer cells, but not BRAF wild-type cells [15].